Literature DB >> 2449922

Proliferation of normal human promyelocytes and myelocytes after a single pulse stimulation by purified GM-CSF or G-CSF.

C G Begley1, N A Nicola, D Metcalf.   

Abstract

Enriched populations of either normal human promyelocytes and myelocytes or blast cells were obtained by fluorescence-activated cell sorting with the monoclonal antibody WEM-G11. These populations were used to study the effect of pulse stimulation by purified recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) or cross-reacting purified murine granulocyte colony-stimulating factor (G-CSF). Maximal clone formation by promyelocytes and myelocytes was observed in 1-mL agar cultures stimulated continuously with 400 units of either CSF and in cultures of cells that were pulse stimulated by 3,200 units (or greater) of either CSF. Pulse stimulation by 800 units of GM-CSF or G-CSF generated 75% clone formation, and pulse stimulation by 200 units CSF gave 50% clone formation. The majority of clones formed by pulse-stimulated cells were only two cells in size; however, some clones were up to 15 cells in size after a single exposure to CSF. Clone formation was not observed in cultures of blast cell populations after a single pulse stimulation with GM-CSF or G-CSF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449922

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies.

Authors:  R P Junghans; J A Carrasquillo; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 2.  Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

Authors:  Hisham Abdel-Azim; Weili Sun; Lingtao Wu
Journal:  Pharmacol Ther       Date:  2019-08-27       Impact factor: 12.310

3.  Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.

Authors:  M Scholz; C Engel; D Apt; S L Sankar; E Goldstein; M Loeffler
Journal:  Cell Prolif       Date:  2009-09-24       Impact factor: 6.831

4.  A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia.

Authors:  M Scholz; M Ackermann; C Engel; F Emmrich; M Loeffler; M Kamprad
Journal:  Cell Prolif       Date:  2009-08-17       Impact factor: 6.831

5.  A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays.

Authors:  R P Junghans
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics.

Authors:  L Oehler; O Majdic; W F Pickl; J Stöckl; E Riedl; J Drach; K Rappersberger; K Geissler; W Knapp
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

7.  A late-lineage murine neutrophil precursor population exhibits dynamic changes during demand-adapted granulopoiesis.

Authors:  Min-Hyeok Kim; Dongchan Yang; Mirang Kim; Seon-Young Kim; Dongsup Kim; Suk-Jo Kang
Journal:  Sci Rep       Date:  2017-01-06       Impact factor: 4.379

8.  Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.

Authors:  Markus Scholz; Manuela Ackermann; Frank Emmrich; Markus Loeffler; Manja Kamprad
Journal:  Biologics       Date:  2009-07-13

9.  Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.

Authors:  Markus Scholz; Sibylle Schirm; Marcus Wetzler; Christoph Engel; Markus Loeffler
Journal:  Theor Biol Med Model       Date:  2012-07-30       Impact factor: 2.432

10.  The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma.

Authors:  G G Steger; R Kaboo; J B deKernion; R Figlin; A Belldegrun
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.